Indivior PLC Ordinary Shares (NASDAQ:INDV) — Market Cap & Net Worth
Market Cap & Net Worth: Indivior PLC Ordinary Shares (INDV)
Indivior PLC Ordinary Shares (NASDAQ:INDV) has a market capitalization of $3.91 Billion ($3.91 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4254 globally and #1443 in its home market, demonstrating a 1.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Indivior PLC Ordinary Shares's stock price $38.01 by its total outstanding shares 124853897 (124.85 Million). Review INDV current and long-term liabilities to assess the company's total debt and financial obligations.
Indivior PLC Ordinary Shares Market Cap History: 2015 to 2026
Indivior PLC Ordinary Shares's market capitalization history from 2015 to 2026. Data shows growth from $289.20 Million to $4.75 Billion (28.03% CAGR).
Index Memberships
Indivior PLC Ordinary Shares is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.16% | #97 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.01% | #474 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.23% | #64 of 263 |
Weight: Indivior PLC Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Indivior PLC Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Indivior PLC Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.31x
Indivior PLC Ordinary Shares's market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
775.97x
Indivior PLC Ordinary Shares's market cap is 775.97 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $443.23 Million | $968.89 Million | $32.05 Million | 0.46x | 13.83x |
| 2017 | $686.57 Million | $1.15 Billion | $60.92 Million | 0.60x | 11.27x |
| 2018 | $168.55 Million | $959.92 Million | $262.67 Million | 0.18x | 0.64x |
| 2019 | $64.92 Million | $815.16 Million | $139.15 Million | 0.08x | 0.47x |
| 2020 | $182.91 Million | $689.68 Million | -$157.76 Million | 0.27x | N/A |
| 2021 | $430.75 Million | $777.48 Million | $205.00 Million | 0.55x | 2.10x |
| 2022 | $2.72 Billion | $884.63 Million | -$52.04 Million | 3.07x | N/A |
| 2023 | $1.91 Billion | $1.09 Billion | $2.00 Million | 1.74x | 953.26x |
| 2024 | $1.55 Billion | $1.19 Billion | $2.00 Million | 1.31x | 775.97x |
Competitor Companies of INDV by Market Capitalization
Companies near Indivior PLC Ordinary Shares in the global market cap rankings as of June 17, 2026.
Key companies related to Indivior PLC Ordinary Shares by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Indivior PLC Ordinary Shares Historical Marketcap From 2015 to 2026
Between 2015 and today, Indivior PLC Ordinary Shares's market cap moved from $289.20 Million to $ 4.75 Billion, with a yearly change of 28.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.75 Billion | +5.94% |
| 2025 | $4.48 Billion | +188.66% |
| 2024 | $1.55 Billion | -18.60% |
| 2023 | $1.91 Billion | -29.79% |
| 2022 | $2.72 Billion | +530.43% |
| 2021 | $430.75 Million | +135.49% |
| 2020 | $182.91 Million | +181.73% |
| 2019 | $64.92 Million | -61.48% |
| 2018 | $168.55 Million | -75.45% |
| 2017 | $686.57 Million | +54.90% |
| 2016 | $443.23 Million | +53.26% |
| 2015 | $289.20 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Indivior PLC Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.91 Billion USD |
| MoneyControl | $3.91 Billion USD |
| MarketWatch | $3.91 Billion USD |
| marketcap.company | $3.91 Billion USD |
| Reuters | $3.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more